Latest News - Multiple Sclerosis & Immune Disorders

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Friday, June 01, 2018

Results for Cladribine For MS Presented at CMSC

Data on use of cladribine tablets (EMD Serono, Rockland, MA) for treatment of relapsing multiple sclerosis (MS) were presented at the Consortium of Multiple Sclerosis Centers (CMSC) meeting in Nashvil…

Read the full story

Wednesday, April 25, 2018

Ocrelizumab Delays Cognitive Decline and Reduces Disease Activity and Disability Progression in Patients With MS

New data on ocrelizumab (OCREVUS; Genentech, South San Francisco, CA) were presented at the American Academy of Neurology this week, including results from 4 years of continuous treatment of patients …

Read the full story

Monday, April 23, 2018

New AAN Guideline: Patients With Multiple Sclerosis Should Start Treatment Early

The American Academy of Neurology (AAN) has released a new guideline for treating patients with multiple sclerosis (MS), which is endorsed by both the National Multiple Sclerosis Society and the Multi…

Read the full story

Monday, April 16, 2018

New Data on Ocrelizumab

Researchers will be presenting, at the upcoming American Academy of Neurology (AAN) meeting beginning on April 21st, 2018, new data on the use of ocrelizumab (OCREVUS; Genentech, San Francisco, CA), w…

Read the full story

Thursday, March 22, 2018

Phase 3 Clinical Trial Shows Siponimod Significantly Improved Outcomes in Patients With Secondary Progressive Multiple Sclerosis

Results from the phase 3 clinical trial, EXPAND, studying oral, once-daily siponimod (Novartis; East Hanover, NJ) for treatment of secondary progressive multiple sclerosis (SPMS) were published today …

Read the full story

Friday, March 16, 2018

Subcutaneous Immune Globulin Approved for Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Already approved in 51 countries for some immune deficiencies, subcutaneous immune globulin (IG) (Hizentra; King of Prussia, PA) has now been approved by the Food and Drug Administration (FDA) for tre…

Read the full story

Friday, March 02, 2018

Consuming Fish and/or Omega-3 Fatty Acids 1-3 Times Per Week May Decrease Risk of Multiple Sclerosis

A preliminary study funded by the National Institute of Neurologic Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), shows that there is a correlation between consumptio…

Read the full story

Thursday, March 01, 2018

Multiple Sclerosis Association of America Kicks Off Understanding Multiple Sclerosis Progression Campaign for Multiple Sclerosis Awareness Month

For multiple sclerosis (MS) Awareness Month, the Multiple Sclerosis Association of America (MSAA) focuses on their campaign on Understanding MS Progression. Specific topics address…

Read the full story

Wednesday, February 21, 2018

Microglia May Promote Recovery of Motor Neurons in Amyotrophic Lateral Sclerosis

In findings published this week in Nature Neuroscience, researchers Krista J. Spiller, Clark R. Restrepo, Tahiyana Khan, and others described creation of a mouse model of amyotrophic lateral sclerosis…

Read the full story

Wednesday, February 14, 2018

New Dose of Generic Glatiramer Acetate Injection for Treatment of Relapsing Multiple Sclerosis Approved by Food and Drug Administration

Sandoz announced that the Food and Drug Administraion (FDA) had approved a generic form of glatiramer acetate (Glatopa,Sandoz) in injectable form at a dose of 40 mg/mL 3 times per week for relapsing f…

Read the full story

Thursday, February 01, 2018

Post Hoc Clinical Trials Data for Cladribine, An Investigational Oral Multiple Sclerosis Treatment

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced that new clinical trial data is being released during the Americas Committee for Treatment and Research in Multi…

Read the full story

Friday, October 27, 2017

ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple sclerosis (MS) who had the disea…

Read the full story

Friday, October 27, 2017

ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS

Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the proportion of patients with …

Read the full story

Friday, October 27, 2017

ECTRIMS: Alkermes Demontrates Safety and GI Tolerability of Investigational Oral Agent for Relapsing MS

Alkermes presented safety and gastrointestinal (GI) tolerability data from EVOLVE-MS-1, an ongoing open-label, two-year phase 3 safety study for ALKS 8700, a novel, oral monomethyl fumarate (MMF) prod…

Read the full story
Load More